Leniolisib not checked
FollowEvery change as it happens, and a Monday email
Trials
3 active
8 in total · 6 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets”In the company’s words, NCT05438407 on ClinicalTrials.gov
- Tested for
- APDS (2 trials), PIDs Linked to PI3K
- Main trialPhase 3
- “This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).”In the company’s words, NCT05438407 on ClinicalTrials.gov
- Other names
- Joenja
Coming up3
- 30 NovPhase 3 trial completes · ClinicalTrials.gov
- 9 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 12 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Nov 2026 | Pediatric Patients Aged 4 to 11 Years With APDS | |
| Phase 3Active, not recruiting | 9 Jul 2028 | Pediatric Patients Aged 1 to 6 Years With APDS | |
| Phase 2Active, not recruiting | 12 Aug 2029 | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation | |
| Phase 3Unknown | 31 Jan 2025 | An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS | |
| Phase 2Completed | 23 Jun 2026 | Leniolisib for Immune Dysregulation in PIDs | |
| Phase 2Completed | 12 Aug 2026 | Leniolisib for Immune Dysregulation in CVID | |
| Phase 1Ended | not given | An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects | |
| Phase 1Ended | not given | A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 70 mg film coated tablet in healthy volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026